FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

8 letters match. Newest first.

  1. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  2. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  3. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  4. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  5. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  6. FirstCham Co., Ltd.

    FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.

    High risk
  7. B & J Group

    B & J Group, a Morrisville, PA contract filler of OTC hand sanitizer, was cited by FDA for skipping finished-product and ingredient testing.

    High risk
  8. McConnell Labs Inc.

    McConnell Labs Inc. released hand sanitizers without raw material identity, finished product, or stability testing, FDA says.

    High risk